The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the ...
Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA will progress its ADC Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown ...
Ovarian cancer is hard to diagnose early. Its symptoms, like bloating and abdominal pain, are vague and similar to other more common conditions. Early diagnosis improves outcomes for many cancers.
Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab ...
BETHESDA, Md., Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific ...
A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer. Age and insurance status were ...
Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results